Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 9/20 | 0.37 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326759 | 0.87 | NLRP3 (0.48) | KCNH2NLRP3IDH1IL1BCNR1 | |
| SCHEMBL30375553 | 0.86 | NLRP3 (0.49) | KCNH2NLRP3IDH1IL1BCNR1 | |
| SCHEMBL26434542 | 0.86 | NLRP3 (0.49) | KCNH2NLRP3IDH1IL1BCNR1 | |
| SCHEMBL26093102 | 0.86 | NLRP3 (0.49) | KCNH2NLRP3IDH1IL1BCNR1 | |
| SCHEMBL29326744 | 0.85 | CDK4 (0.38) | IL1B | |
| SCHEMBL29326723 | 0.84 | NLRP3 (0.64) | KCNH2NLRP3IDH1IL1BCNR1 | |
| SCHEMBL29326726 | 0.82 | NLRP3 (0.61) | KCNH2NLRP3IDH1IL1B | |
| SCHEMBL29326755 | 0.82 | KCNH2 (0.46) | KCNH2NLRP3IDH1IL1BCNR1 | |
| SCHEMBL29326781 | 0.79 | IL1B (0.43) | KCNH2NLRP3IL1BCNR1CNR2 | |
| SCHEMBL29326775 | 0.77 | IL1B (0.61) | NLRP3IL1BCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | KCNH2 2120/4885NLRP3 1/4885IDH1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.